GRO Biosciences Raises $25M in Series A Funding

Gro Bioscences

Gro Bioscences, a Boston MA-based biotechnology company advancing protein therapeutics, raised $25M in Series A funding.

The round was led by Leaps by Bayer and Redmile Groupwith participation from Digitalis Ventures and Innovation Endeavors.

The company intends to use the funds to scale-up its bioprocess manufacturing, preclinical validation studies and IND-enabling studies for its pipeline of non-standard amino acid (NSAA) protein therapeutics to treat autoimmune and metabolic diseases.

Led by Daniel J. Mandell, PhD, CEO, GRO Biosciences is a biotechnology company leveraging science to expand the amino acid alphabet and advance protein therapeutics in diverse areas including autoimmune and metabolic diseases. The company is applying its platform to advance partnered and collaborative programs, as well as its own pipeline of protein therapeutics bearing unique NSAA (non-standard amino acid) chemistries.

The proprietary platform, developed in the labs of Dr. George Church, is comprised of the first production organisms with modified genomes that enable the production of proteins with NSAAs – protein building blocks that expand beyond the typical 20 amino acids. The company’s scalable and stable production platform delivers protein therapeutics with chemistries and properties previously inaccessible to protein engineering.